Literature DB >> 10774785

Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents.

Y Edoute1, P Nagachandran, B Svirski, H Ben-Ami.   

Abstract

Numerous studies have shown a beneficial effect of combination therapy with beta-blockers and calcium antagonists in patients with anginal syndrome and/or hypertension. However, because both agents exert a negative chronotropic effect, their combined use may cause bradyarrhythmias with resultant symptoms of cerebral, coronary, and systemic hypoperfusion. We describe our clinical experience with patients who had cardiovascular adverse drug reactions (CVADRs) with combination therapy. This prospective study included 26 patients who had CVADRs among 2,574 admissions during a 2-year period. The study group included 14 men and 12 women with a median age of 73 years. Various combinations of calcium antagonists and beta-blockers were associated with the CVADRs. The most frequent pharmacologic combination was diltiazem plus propranolol. The CVADRs were the cause for hospital admission in 10 patients, an associated cause in nine patients, and developed during hospitalization in seven patients. Cardiac bradyarrhythmias were found in 22 patients. These rhythm abnormalities resolved within 24 h after discontinuation of the offending drugs. Temporary transvenous pacemaker insertion was necessary in only one patient with complete atrioventricular block. Twenty-two patients recovered, two patients died of pump failure not associated with CVADRs, and in two patients, the CVADRs contributed to the patients' death. CVADRs are not uncommon in elderly patients with ischemic heart disease and/or hypertension treated with the concomitant use of calcium antagonist and beta-adrenergic blocking drugs. Use of calcium antagonist plus beta-blocker may unpredictably cause serious hemodynamic events, marked suppression of sinus node activity, and prolongation of atrioventricular conduction in some patients. Enhanced therapeutic monitoring may be warranted when calcium antagonists are combined with beta-blockers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10774785     DOI: 10.1097/00005344-200004000-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Prevalence of adverse drug combinations in a large post-mortem toxicology database.

Authors:  Terhi Launiainen; Erkki Vuori; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2008-06-27       Impact factor: 2.686

2.  Adverse effects using combined rate-slowing antihypertensive agents.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-06-20       Impact factor: 3.738

Review 3.  Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.

Authors:  Cheryl D Bushnell; Cathleen S Colón-Emeric
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

4.  Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study.

Authors:  Hou Tee Lu; Jiyen Kam; Rusli Bin Nordin; Surinder Kaur Khelae; Jing Mein Wang; Chun Ngok Choy; Chuey Yan Lee
Journal:  J Geriatr Cardiol       Date:  2016-09       Impact factor: 3.327

5.  Prognosis and natural history of drug-related bradycardia.

Authors:  Jang Hoon Lee; Hyeon Min Ryu; Myung Hwan Bae; Yong Seop Kwon; Ju Hwan Lee; Yongwhi Park; Jung-Ho Heo; Young Soo Lee; Dong Heon Yang; Hun Sik Park; Yongkeun Cho; Shung Chull Chae; Yoon-Nyun Kim; Jae-Eun Jun; Wee-Hyun Park
Journal:  Korean Circ J       Date:  2009-09-30       Impact factor: 3.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.